Oliveras Ferrarós, Cristina (Date of defense: 2013-06-21)
The aim of this doctoral thesis was to unravel mechanisms underlying primary resistance to trastuzumab regarding a putative new breast cancer subtype with mixed basal & ErbB2+ molecular features. Using ...
Ferri Iglesias, María José (Date of defense: 2012-09-27)
Serum levels of several molecules associated to pancreatic adenocarcinoma (PDAC) pathophysiology are evaluated in this work, in order to determine their diagnostic value, distinguishing between PDAC ...
Carrion-Salip, Dolors (Date of defense: 2014-09-17)
Most current chemotherapeutic agents are of limited use due to their side effects and the resistance to treatment that tumour cells develop. In this thesis, we have contributed to the knowledge of these ...
Cufí González, Sílvia (Date of defense: 2015-05-22)
Aquest és el primer informe que demostra que l'autofàgia està mecànicament vinculat al manteniment de les cèl•lules tumorals que expressen alts nivells de CD44 i baixos nivells de CD24, que són típics ...
Balmaña Esteban, Meritxell (Date of defense: 2016-07-07)
Cancer is one of the leading causes of death worldwide. Pancreatic ductal adenocarcinoma (PDAC) is characterized by high intrinsic aggressiveness and late diagnosis, causing poor prognosis and resulting ...
Panosa Roqueta, Clara (Date of defense: 2015-12-14)
The members of the epidermal growth factor (EGF) / ErbB family are prime targets for cancer therapy. However, the therapeutic efficiency of the existing anti-ErbB agents is limited. Thus, identifying ...
Blanco Aparicio, Carmen (Date of defense: 1998-07-17)
In this work we report that potato carboxypeptidase inhibitor suppresses the growth of several human and mouse pancreatic adenocarcinoma cell lines. The inhibitor also reduces the growth of solid tumors ...
Bravo Bonilla, Marlon Rolando (Date of defense: 2022-06-16)
Cancer is the leading cause of death due to non-communicable diseases worldwide. Despite the advances in the development of new antitumor drugs, there are still problems such as the resistance that tumor ...
Miró Domènech, Laura (Date of defense: 2023-01-13)
Pancreatic ductal adenocarcinoma (PDA) presents a dismal prognosis mainly due to its delayed diagnosis, its aggressiveness, and resistance to existing therapies. Aberrant glycosylation and, in particular, ...
Duran Sidera, Adrià (Date of defense: 2023-11-14)
Pancreatic cancer (PaC) is the deadliest of all tumours, with a 5-year survival below 12% and a mortality/incidence ratio of 94.5%. One of the main reasons behind this dismal prognosis is the diagnosis ...